Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery

Current Opinion in Pharmacology

Volumn 5, Issue 4 SPEC. ISS., 2005, Pages 350-356

  Thompson, Neil ^a   Lyons, John ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ARRY 142886; AZD 6244; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; GUANOSINE TRIPHOSPHATASE; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OXALIPLATIN; PACLITAXEL; PROTEIN KINASE INHIBITOR; RAF PROTEIN; SORAFENIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVATION; GENE MUTATION; GENETIC ASSOCIATION; GLIOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; REVIEW;

EID: 21644440921     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.04.007     Document Type: Review

References (21)

1. H.R. Bourne D.A. Sanders F. McCormick The GTPase superfamily: A conserved switch for diverse cell functions Nature 348 1990 125-132
2. H.R. Bourne D.A. Sanders F. McCormick The GTPase superfamily: Conserved structure and molecular mechanism Nature 349 1991 117-127
3. P. Rodriguez-Viciana C. Sabatier F. McCormick Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate Mol Cell Biol 24 2004 4943-4954
4. J.L. Bos The ras gene family and human carcinogenesis Mutat Res 195 1988 255-271
5. J.L. Bos ras oncogenes in human cancer: A review Cancer Res 49 1989 4682-4689
6. H. Davies G.R. Bignell C. Cox P. Stephens S. Edkins S. Clegg J. Teague H. Woffendin M.J. Garnett W. Bottomley et al. Mutations of the BRAF gene in human cancer Nature 417 2002 949-954
7. P. Stephens C. Hunter G. Bignell S. Edkins H. Davies J. Teague C. Stevens S. O'Meara R. Smith A. Parker et al. Lung cancer: Intragenic ERBB2 kinase mutations in tumours Nature 431 2004 525-526
8. T.J. Lynch D.W. Bell R. Sordella S. Gurubhagavatula R.A. Okimoto B.W. Brannigan P.L. Harris S.M. Haserlat J.G. Supko F.G. Haluska et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129-2139
9. G. Bollag S. Freeman J.F. Lyons L.E. Post Raf pathway inhibitors in oncology Curr Opin Investig Drugs 4 2003 1436-1441
10. J.F. Lyons S. Wilhelm B. Hibner G. Bollag Discovery of a novel Raf kinase inhibitor Endocr Relat Cancer 8 2001 219-225
11. M.J. Arboleda D. Eberwein B. Hibner J.F. Lyons Dominant negative mutants of mitogen-activated protein kinase pathway Methods Enzymol 332 2001 353-367
12. P.T. Wan M.J. Garnett S.M. Roe S. Lee D. Niculescu-Duvaz V.M. Good C.M. Jones C.J. Marshall C.J. Springer D. Barford et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855-867
13. S. Wilhelm D.S. Chien BAY 43-9006: Preclinical data Curr Pharm Des 8 2002 2255-2257
14. S.M. Wilhelm C. Carter L. Tang D. Wilkie A. McNabola H. Rong C. Chen X. Zhang P. Vincent M. McHugh et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099-7109
15. S. Chow H. Patel D.W. Hedley Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors Cytometry 46 2001 72-78
16. A. Chiloeches H.F. Paterson R. Marais A. Clerk C.J. Marshall P.H. Sugden Regulation of Ras.GTP loading and Ras-Raf association in neonatal rat ventricular myocytes by G protein-coupled receptor agonists and phorbol ester. Activation of the extracellular signal-regulated kinase cascade by phorbol ester is mediated by Ras J Biol Chem 274 1999 19762-19770
17. R.A. Hilger S. Kredke D. Hedley J.G. Moeller R.J. Bauer W. Stellberg S. Seeber M.E. Scheulen D. Strumberg ERK1/2 phosphorylation: A biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006 Int J Clin Pharmacol Ther 40 2002 567-568
18. D. Strumberg H. Richly R.A. Hilger N. Schleucher S. Korfee M. Tewes M. Faghih E. Brendel D. Voliotis C.G. Haase et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 23 2005 965-972
19. J.S. Sebolt-Leopold D.T. Dudley R. Herrera K. Van Becelaere A. Wiland R.C. Gowan H. Tecle S.D. Barrett A. Bridges S. Przybranowski et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo Nat Med 5 1999 810-816
20. J.S. Sebolt-Leopold R. Herrera Targeting the mitogen-activated protein kinase cascade to treat cancer Nat Rev Cancer 4 2004 937-947
21. A. Awada A. Hendlisz T. Gil S. Bartholomeus M. Mano D. de Valeriola D. Strumberg E. Brendel C.G. Haase B. Schwartz M. Piccart Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours Br J Cancer 92 2005 1855-1861